The clinical responses observed following treatment with immune checkpoint inhibitors
(ICIs) support immunotherapy as a potential anticancer treatment. However, a large …

Myeloid-derived suppressor cells (MDSCs) are pathologically activated neutrophils and
monocytes with potent immunosuppressive activity. They are implicated in the regulation of …

Anticancer nanomedicines have been proven effective in mitigating the side effects of
chemotherapeutic drugs. However, challenges remain in augmenting their therapeutic …

Despite the remarkable success of immune checkpoint inhibitors (ICIs) in melanoma
treatment, resistance to them remains a substantial clinical challenge. Myeloid-derived …

The successful outcomes of chimeric antigen receptor (CAR) T-cell therapy in treating
hematologic cancers have increased the previously unprecedented excitement to use this …

Myeloid-derived suppressor cells (MDSC) are important regulators of immune responses in
cancer. They represent a relatively stable form of pathologic activation of neutrophils and …

Our understanding of the role of myeloid-derived suppressor cells (MDSCs) in cancer is
becoming increasingly complex. In addition to their eponymous role in suppressing immune …

Myeloid-derived suppressor cells (MDSCs) possess immunosuppressive activities, which
allow cancers to escape immune surveillance and become non-responsive to immune …

Chimeric antigen receptor (CAR)-T cell therapy has achieved successful outcomes against
hematological malignancies and provided a new impetus for treating solid tumors. However …

Cancer immunotherapies that harness the body's immune system to combat tumors have
received extensive attention and become mainstream strategies for treating cancer. Despite …